๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Rituximab in ANCA-Associated Vasculitis: Fad or Fact?

โœ Scribed by Fervenza, Fernando C.

Book ID
120256118
Publisher
S. Karger AG
Year
2011
Tongue
English
Weight
199 KB
Volume
118
Category
Article
ISSN
0028-2766

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Rituximab versus Cyclophosphamide for AN
Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis
โœ Stone, John H.; Merkel, Peter A.; Spiera, Robert; Seo, Philip; Langford, Carol A ๐Ÿ“‚ Article ๐Ÿ“… 2010 ๐Ÿ› Massachusetts Medical Society ๐ŸŒ English โš– 424 KB

## Background: Cyclophosphamide and glucocorticoids have been the cornerstone of remission-induction therapy for severe antineutrophil cytoplasmic antibody (anca)-associated vasculitis for 40 years. uncontrolled studies suggest that rituximab is effective and may be safer than a cyclophosphamide-ba

Rituximab versus Cyclophosphamide in ANC
Rituximab versus Cyclophosphamide in ANCA-Associated Renal Vasculitis
โœ Jones, Rachel B.; Cohen Tervaert, Jan Willem; Hauser, Thomas; Luqmani, Raashid; ๐Ÿ“‚ Article ๐Ÿ“… 2010 ๐Ÿ› Massachusetts Medical Society ๐ŸŒ English โš– 408 KB

## Background: Cyclophosphamide induction regimens for antineutrophil cytoplasmic antibody (anca)-associated vasculitis are effective in 70 to 90% of patients, but they are associated with high rates of death and adverse events. treatment with rituximab has led to remission rates of 80 to 90% among